Patents Assigned to SUNG KYUN BIOTECH CO., LTD.
-
Patent number: 11827696Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: GrantFiled: December 16, 2021Date of Patent: November 28, 2023Assignee: Sung Kyun Biotech Co., Ltd.Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
-
Patent number: 11746146Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: GrantFiled: December 16, 2021Date of Patent: September 5, 2023Assignee: SUNG KYUN BIOTECH CO., LTD.Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
-
Patent number: 11732035Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: GrantFiled: December 16, 2021Date of Patent: August 22, 2023Assignee: Sung Kyun Biotech Co., Ltd.Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
-
Patent number: 11498945Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: GrantFiled: November 28, 2017Date of Patent: November 15, 2022Assignee: Sung Kyun Biotech Co., Ltd.Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
-
Publication number: 20220106368Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: ApplicationFiled: December 16, 2021Publication date: April 7, 2022Applicant: SUNG KYUN BIOTECH CO., LTD.Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
-
Publication number: 20220106369Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: ApplicationFiled: December 16, 2021Publication date: April 7, 2022Applicant: SUNG KYUN BIOTECH CO., LTD.Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
-
Patent number: 11058740Abstract: The present disclosure relates to a composition for preventing, alleviating or treating stress diseases, containing a Platycodon grandiflorum extract as an active ingredient, and, more specifically, to a food composition for preventing or alleviating stress diseases or a pharmaceutical composition for preventing and treating stress diseases, both of which contain a Platycodon grandiflorum extract and a Citrus aurantium extract as active ingredients. A method of the present disclosure can be used for the preparation of an agent for treating depression and anxiety, which are stress diseases, with few side effects because of the use of a natural material, and a health functional food having effects of alleviating depression, anxiety and fatigue, which are stress diseases.Type: GrantFiled: April 18, 2018Date of Patent: July 13, 2021Assignee: SUNG KYUN BIOTECH CO., LTD.Inventors: Mi Rim Jin, Do Heon Lee, Sun Yeou Kim
-
Publication number: 20200113962Abstract: The present disclosure relates to a composition for preventing, alleviating or treating stress diseases, containing a Platycodon grandiflorum extract as an active ingredient, and, more specifically, to a food composition for preventing or alleviating stress diseases or a pharmaceutical composition for preventing and treating stress diseases, both of which contain a Platycodon grandiflorum extract and a Citrus aurantium extract as active ingredients. A method of the present disclosure can be used for the preparation of an agent for treating depression and anxiety, which are stress diseases, with few side effects because of the use of a natural material, and a health functional food having effects of alleviating depression, anxiety and fatigue, which are stress diseases.Type: ApplicationFiled: April 18, 2018Publication date: April 16, 2020Applicant: SUNG kyun BIOTECH CO.. LTD,Inventors: Mi Rim JIN, Do Heon LEE, Sun Yeou KIM
-
Publication number: 20200010518Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.Type: ApplicationFiled: November 28, 2017Publication date: January 9, 2020Applicant: SUNG KYUN BIOTECH CO., LTD.Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
-
Patent number: 10494356Abstract: The present disclosure relates to a compound having the activity of promoting osteoblast differentiation and inhibiting adipocyte differentiation and a preparation method thereof. The novel compound of the present disclosure increases the expression of the gene ALP involved in the differentiation of osteoblasts, regulates expression of the genes PPAR?, aP2 and CD36 involved in the differentiation of adipocytes, increases bone mineral density (BMD) in an ovariectomized osteoporosis animal model and decreases adipocytes in the bone marrow. Therefore, it can be used as an active ingredient of a medication or a health functional food useful for metabolic bone disease or obesity.Type: GrantFiled: May 12, 2017Date of Patent: December 3, 2019Assignee: SUNG KYUN BIOTECH CO., LTD.Inventors: Hyun Suk Kim, Kimoon Park, Min-hyuk Bang, Hee-Jin Yang, Yun Mi Lee, Ki Hyun Kim
-
Publication number: 20190152935Abstract: The present disclosure relates to a compound having the activity of promoting osteoblast differentiation and inhibiting adipocyte differentiation and a preparation method thereof. The novel compound of the present disclosure increases the expression of the gene ALP involved in the differentiation of osteoblasts, regulates expression of the genes PPAR?, aP2 and CD36 involved in the differentiation of adipocytes, increases bone mineral density (BMD) in an ovariectomized osteoporosis animal model and decreases adipocytes in the bone marrow. Therefore, it can be used as an active ingredient of a medication or a health functional food useful for metabolic bone disease or obesity.Type: ApplicationFiled: May 12, 2017Publication date: May 23, 2019Applicant: SUNG KYUN BIOTECH CO., LTD.Inventors: Hyun Suk KIM, Kimoon PARK, Min-hyuk BANG, Hee-Jin YANG, Yunmi LEE, Ki Hyun KIM
-
Publication number: 20150157675Abstract: The present invention relates to a Eupatorium spp. extract having anti-obesity effects as a result of decreasing adipocytes and increasing osteoblasts, as well as the effects of preventing bone disease or fractures by increasing osteoblasts and of preventing osteoporosis by decreasing adipocytes and increasing osteoblasts by the same proportion in mesenchymal stem cells. DCM fraction layers of a Eupatorium spp. stem extract collected on a monthly basis and Eupatorium spp. stem extract collected only in September may inhibit the activity of PPAR?, AP2, CD36, adiponectin C/EBP?, and LPL, which serve as significant factors for adipocyte differentiation in C3H10T1/2 cells and primary mesenchymal stem cells, which are pluripotent stem cell lines, and may increase the activity of ALP, osterix, CO1I and RUNX2, which serve as significant factors for osteoblast differentiation. The Eupatorium spp.Type: ApplicationFiled: April 2, 2012Publication date: June 11, 2015Applicants: SUNG KYUN BIOTECH CO., LTD., REPUBLIC OF KOREA (MANAGEMENT:RURAL DEVELOPMENT ADMINISTRATION)Inventors: Hyun Seok Kim, Ki Moon Park, Min Ji Kim, Youngmin Lee, Haeng Ran Kim, Kang Jin Cho